83624-01-5

Basic information

• Product Name: (2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid
• Synonyms: (2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid;(4R)-1-Boc-4-methoxy-L-proline
• CAS NO: 83624-01-5
• Molecular Formula: C₁₁H₁₉NO₅
• Molecular Weight: 245.27226
• Mol File: 83624-01-5.mol

Chemical Properties

• Boiling Point: 362.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.20±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.75±0.40(Predicted)
• CAS DataBase Reference: (2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid(83624-01-5)
• EPA Substance Registry System: (2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid(83624-01-5)

Safety Data

• Hazardous Substances Data: 83624-01-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid is used as a key intermediate in organic synthesis for the preparation of various chemical compounds. Its unique structure and functional groups allow for selective reactions and the formation of diverse products.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid is used as a building block for the synthesis of drug candidates. Its versatility and reactivity enable the development of new drugs with potential therapeutic applications.
Used in Chemical Research:
(2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid is utilized in chemical research as a model compound to study various reaction mechanisms and explore new synthetic routes. Its unique properties and reactivity provide valuable insights into the field of organic chemistry.
Used in Material Science:
In material science, (2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid is employed as a precursor for the development of novel materials with specific properties. Its ability to undergo various reactions allows for the creation of materials with tailored characteristics for different applications.

Upstream product

• 426844-31-7 methyl 1-(tert-butoxycarbonyl)-(4R)-methoxypyrrolidine-(2S)-carboxylate 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 67-63-0 isopropyl alcohol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 
• 51-35-4 4R-4-hydroxyproline 
• 96522-36-0 (2S,4R)-4-methoxypyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 13504-85-3 (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 

Downstream Products

• 886447-79-6 ethyl [1-[1-(tert-butoxycarbonyl)-(4R)-methoxy-(2S)-pyrrolidinylcarbony]-4-piperidinyl]acetate 
• 886447-47-8 ethyl 4-[4-methoxy-1-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinylcarbonyl]-1-piperazinylacetate 
• 886447-59-2 ethyl [1-[(4R)-methoxy-1-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinylcarbonyl]-4-piperidinyl]acetate 
• 75176-09-9 (2S,4R)-4-methoxypyrrolidine-2-carboxylic acid 
• 1178549-19-3 N-tert-butoxycarbonyl-(2S,4R)-4-methoxyprolylglycine benzyl ester 
• 1445591-89-8 (2S,4R)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4-methoxypyrrolidine-carboxylate 
• 1445591-90-1 methyl ((S)-1-((2S,4R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4-methoxypyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
• 1445590-75-9 methyl ((S)-1-((2S,4R)-4-methoxy-2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
• 1609261-17-7 (2S,4R)-1-(4-(benzyloxy)-3,5-dimethoxybenzoyl)-4-methoxy-pyrrolidine-2-carboxylic acid 
• 1609261-26-8 (S)-1-((2S,4R)-1-(4-(benzyloxy)-3,5-dimethoxybenzoyl)-4-methoxypyrrolidine-2-carbonyl)pyrrolidine-2-carbonitrile 

Relevant articles and documents

MACROCYCLIC RIP2-KINASE INHIBITORS

The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2-kinase, and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.

PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS

The present invention provides pyridazine derivatives of formula (I), which are therapeutically useful as SMARCA2/4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2/4 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the pyridazine derivatives of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof.

N-methyl-D-aspartate receptor modulators and methods of making and using same

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2

Transglutaminase 2 (TG2) is a ubiquitously expressed enzyme that catalyzes the posttranslational modification of glutamine residues on protein or peptide substrates. A growing body of literature has implicated aberrantly regulated activity of TG2 in the pathogenesis of various human inflammatory, fibrotic, and other diseases. Taken together with the fact that TG2 knockout mice are developmentally and reproductively normal, there is growing interest in the potential use of TG2 inhibitors in the treatment of these conditions. Targeted-covalent inhibitors based on the weakly electrophilic 3-bromo-4,5-dihydroisoxazole (DHI) scaffold have been widely used to study TG2 biology and are well tolerated in vivo, but these compounds have only modest potency, and their selectivity toward other transglutaminase homologues is largely unknown. In the present work, we first profiled the selectivity of existing inhibitors against the most pertinent TG isoforms (TG1, TG3, and FXIIIa). Significant cross-reactivity of these small molecules with TG1 was observed. Structure-activity and -selectivity analyses led to the identification of modifications that improved potency and isoform selectivity. Preliminary pharmacokinetic analysis of the most promising analogues was also undertaken. Our new data provides a clear basis for the rational selection of dihydroisoxazole inhibitors as tools for in vivo biological investigation.

Effect of proline analogues on the conformation of elastin peptides

Three elastin model peptides containing the repetitive motif -VGVXGVG-, where X corresponds to (2S)-proline (Pro), (2S,4R)-4-hydroxy-proline (Hyp) and (2S,4R)-4-methoxy-proline (Mop), were synthesized in order to define the effect of the introduction of an electronegative group on the conformation and self-assembling properties of the peptides. Circular dichroism, NMR and FT-IR spectroscopies evidenced outstanding differences at molecular and supramolecular level. This work constitutes the basis for the proper design of elastin-inspired drugs with tailored conformational properties.

PYRROLOTRIAZINE KINASE INHIBITORS

The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.

Stabilization of the collagen triple helix by O-methylation of hydroxyproline residues

Collagen is the most abundant protein in animals, including humans. The prevalent (2S,4R)-4-hydroxyproline (Hyp) residues of collagen are known to confer great stability upon its triple-helical conformation. The basis for that stability has been attribute

VLA-4 INHIBITOR

An object of the present invention is to provide a compound which selectively inhibits binding of a ligand and ±421 integrin (VLA-4), a process for producing the compound, and a medicament containing the compound. A compound represented by the formula (I) etc. orasaltthereof, a process for producing the compound or a salt thereof, a medicament containing the compound or a salt thereof, as well as a preventive and/or a therapeutic agent for a disease caused by cell adhesion, for example, inflammatory reaction, autoimmune disease, cancer metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease and rejection reaction at transplantation, containing the compound or a salt thereof as a primary component. [wherein Y 1 represents a divalent aryl group etc. , V 1 represents an aryl group etc., and R 11 to R 14 represent H, OH or a halogen atom etc.]

N-Aryl Pyrrolidine Derivatives as Beta-Secretase Inhibitors

There is provided a series of substituted N-aryl pyrrolidine derivatives of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R5′, R6, R7, and p as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.